SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.84+1.8%Dec 19 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Elmer who wrote (1461)8/25/2000 8:06:10 AM
From: scaram(o)uche  Read Replies (2) of 52153
 
David:

A second answer to your question.... yes, Idec also reported progress before the project was eventually dropped.

The Idec effort came in two flavors. The really, really, really dumb one was called "Specifid". My criticism was contemporaneous...... this is not 20-20 hindsight.

So...... yes, there's a history of enthusiasm and then failure, with a related effort.

Real quickly..... try searching the Vical 10-K for "lymphoma". If you find an active project, ask IR at DNDN if a similar concept to Mylovenge, applied to lymphoma, has influenced their selection of multiple myeloma as an initial focus (you could try a Medline search to see if "somatic mutation" is minimal in MM). If you could come up with the old Idec 10-Ks, you'd get a good concept of how long a company can describe a lousy project in glowing terms.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News